Zacks Industry Outlook Philip Morris, British American Tobacco and Altria

Zacks ranks the tobacco industry #234 out of more than 248 industries, placing it in the bottom 6% on a negative aggregate earnings outlook. The group gained 4.4% over the past year, ahead of consumer staples' 1.2% return but well below the S&P 500's 16.8%, while trading at 14.9x forward P/E versus 19.83x for the S&P 500. Persistent cigarette-volume declines, inflation-driven input costs and regulation remain near-term headwinds, although PM, BTI and MO are investing in heated tobacco, vapor and oral nicotine; PM's 2026 and 2027 EPS estimates rose by $0.03 each to $8.36 and $9.19.

Analysis

This is not a new fundamental catalyst; it reinforces the key dispersion trade within tobacco. PM has the clearest path to a higher-quality earnings mix because smoke-free growth can offset volume decline while utilizing its global distribution base. BTI and MO remain more dependent on extracting price from mature combustible franchises, making their earnings more vulnerable if down-trading accelerates or regulators constrain flavored nicotine products.

The important second-order issue is that oral-nicotine category growth is not automatically margin-accretive: retailer slotting, promotional spending and manufacturing scale-up can delay operating leverage. PM's valuation premium is justified only if ZYN growth remains incremental rather than cannibalizing high-margin cigarettes; MO's on! requires sustained share gains to avoid becoming a cost center. Over the next 1-3 months, quarterly category-volume and U.S. convenience-store scanner data matter more than minor consensus-EPS changes.

Contrarian view: broad tobacco pessimism may overstate near-term downside because nicotine demand is relatively inelastic and price/mix can protect cash flow even under declining unit volumes. But a sector-wide rerating is unlikely over 6-18 months: regulatory optionality, not low headline P/E, determines terminal multiples. The material downside trigger is FDA action affecting flavored vapor or oral nicotine, which would hit BTI's Vuse/Velo and MO's growth investments while potentially strengthening PM's heated-tobacco positioning.

Key Decisions for Investors

• Initiate a 3-6 month long PM / short BTI pair, sized dollar-neutral. PM offers the superior smoke-free execution and estimate-revision setup; BTI has greater regulatory and category-execution uncertainty. Target 8-12% relative return; exit if PM's smoke-free net-revenue growth decelerates below management's medium-term trajectory or BTI delivers two consecutive quarters of New Categories margin expansion.
• Maintain MO as an income hold rather than add exposure before U.S. oral-nicotine share data confirm on! momentum. A favorable entry requires evidence of share gains without incremental promotional intensity; otherwise the dividend yield can mask deteriorating franchise value over 6-18 months.
• Set event alerts around FDA enforcement, marketing-authorization decisions and any proposed nicotine-cap timetable. Reduce tobacco beta immediately on broad flavor restrictions; consider PM-over-MO relative longs if enforcement is targeted at U.S. vapor/oral products.
• Do not trade QBTS on this item; its inclusion in the supplied ticker set has no identifiable economic linkage to tobacco fundamentals.